

Shionogi to Announce Corporate Reorganization and Personnel Reassignment

Osaka, Japan, February 28, 2018 - Shionogi & Co., Ltd. (Head Office: Osaka; President & CEO: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) announced that Shionogi will implement the following corporate reorganization and personnel reassignments as of April 1, 2018.

1. Corporate Reorganization (see attached organization charts)

(1) Shionogi has been integrating and strengthening its supply chain functions in the SCM Division and has made some progress in that context. At this time, therefore, we are positioned to further advance our SCM approach, dissolving the SCM Division, establishing a Strategic Supply Chain Planning Office under the Corporate Planning Department, and integrating the current Supply Operation Department into the Manufacturing Division to further strengthen the SCM strategy and practical operations.

(2) To further expand its global business, Shionogi will restructure its related organizations, and establish a new European and US Operations Department which will manage the US and European group companies, as well as a new Global Business Department which will manage global sales functions of rest of the world, mainly China and Taiwan, both under the Global Business Division. Current business functions in the SCM Division responsible for the supply of active pharmaceutical ingredients will also be integrated into the Global Business Department.

(3) In order to strengthen our product management capabilities, the current Product Planning Group and Portfolio Management Office in the Corporate Planning Department will be integrated and a new Product Management Office will be established. In addition, the Pre-Launch Marketing Office in the Human Health Care Division and other marketing analysis functions in each value chain will be integrated into the Product Management Office.

(4) The current Regulatory Affairs Department in the Corporate Quality Management Division will be moved into the Global Development Division to support earlier submission of drug applications and to successfully obtain approvals for global pipeline compounds through stronger and more effective collaboration between regulatory functions and clinical development. Shionogi will also reorganize its regulatory functions in the Corporate Quality Management Division, including part of the current Regulatory Affairs Department, and establish a new Regulatory Compliance Management Department to strengthen product compliance post-marketing both inside and outside Japan.

(5) Society has been seeking greater and greater corporate social responsibility (CSR) recently. To meet these demands, Shionogi will establish a new Corporate Social Responsibility Department to pursue all CSR activities, both focusing on innovative drug discovery and fulfilling its responsibilities to the economy, society and the environment. To fully enable this new Department to achieve the above responsibilities, the compliance and risk management functions and the EHS Office in the Human Resources & Administration Department and the Office for Children’s Bright Future in the Corporate Planning Department will be moved into the Corporate Social Responsibility Department. Shionogi will also integrate its activities for the proper use of pharmaceutical products in the current Antimicrobial Stewardship Office and Pain Management Office, currently in the Human Health Care Division, and will establish the Office of Stewardship for the Proper Use of Medicine in the Corporate Social Responsibility Department.

(6) To carefully reflect changes in the Japanese commercial business environment in its regional strategy, regional support functions in the Product Marketing Department will be integrated into the current Medical Relations Office in the Human Health Care Division, thereby establishing the Regional Strategic Planning and Healthcare Relations Department.

(7) To enhance open innovation, the incubation functions of the Global Innovation Office in the Pharmaceutical Research Division will be integrated into the Business Development Department, and the other current functions of the Global Innovation Office will remain in the Pharmaceutical Research Division and renamed the Research Management & Planning Office.

2. Personnel Reassignments (Effective; April 1, 2018)

New (or Continuing) Position	Name	Present Position
Pharmaceutical Research Division		
Vice President, Drug Discovery & Disease Research Laboratory	Minoru Hasegawa	Senior Director, Drug Discovery & Disease Research Laboratory
Vice President, Research Laboratory for Development	Masashi Deguchi	Vice President, Drug Discovery & Disease Research Laboratory
Senior Director, Research Management & Planning Office	Mina Yamamoto	Director, Global Innovation Office
Global Development Division		
Corporate Officer, Senior Vice President, Global Development Division	Toshinobu Iwasaki	Corporate Officer, Senior Vice President, Corporate Quality Management Division
Vice President, Clinical Research Department	Yoichi Sato	Vice President, Regulatory Affairs Department
Vice President, Regulatory Affairs Department	Chie Kishimoto	Senior Director, Office for Children's Bright Future
Senior Director, Biostatistics Center	Yasuyuki Ariyasu	Senior Director, Regulatory Compliance Office
CMC R&D Division		
Senior Executive Officer, Senior Vice President, CMC R&D Division	Ryuichi Kume	Senior Executive Officer, Senior Vice President, Human Health Care Division
Vice President, API R&D Center	Yasunori Aoyama	Senior Director, Medicinal Chemistry Research Laboratory
Vice President, Formulation R&D Center	Yasuyoshi Isou	Vice President, IMP Manufacturing Center
Vice President, Analytical R&D Center	Kakuji Yoshihara	President, Shionogi Analysis Center Co., Ltd.
Vice President, IMP Manufacturing Center	Yoshitsugu Muguruma	Senior Director, Production Technology Department
Manufacturing Division		
Vice President, Manufacturing Division	Yoshihiro Furuya	Vice President, Regulatory Compliance Office
Vice President, Production Technology Department	Masanori Nishiwaki	Senior Director, Production Technology Department
Vice President, Supply Operation Department	Kohei Murashima	Vice President, Supply Operation Department, SCM Division

Human Health Care Division		
Corporate Officer, Senior Vice President, Human Health Care Division	Kazuhiro Hatanaka	Corporate Officer, Senior Vice President, Global Development Division
Vice President, Human Health Care Division	Masao Kashiyama	Vice President, Pharmaceutical Promotion Department - Region 3
Vice President, Pharmaceutical Promotion Department - Region 2	Naoto Furuta	Vice President, Pharmaceutical Promotion Department - Region 4
Vice President, Pharmaceutical Promotion Department - Region 3	Minoru Mitsuda	Senior Director, Pharmaceutical Promotion Department - Region 3
Vice President, Pharmaceutical Promotion Department - Region 4	Hideo Kawamura	Senior Director, Pharmaceutical Promotion Department - Region 2
Vice President, Regional Strategic Planning and Healthcare Relations Department	Harumi Shimazui	Vice President, Sales Planning Department
Vice President, Sales Planning Department	Susumu Mitsumori	Senior Director, Sales Planning Department
Corporate Quality Management Division		
Corporate Officer, Senior Vice President, Corporate Quality Management Division, and General Marketing Compliance Officer	Miyuki Hiura	Corporate Officer, Senior Vice President, CMC R&D Division
Vice President, Regulatory Compliance Management Department	Minako Kubo	Senior Director, Quality Assurance Department
Global Business Division		
Senior Executive Officer, Senior Vice President, Global Business Division, and Head, European and US Operations	John Keller	Senior Executive Officer, President & CEO, Shionogi Inc.
Vice President, Global Business Department	Tatsumori Yoshida	Vice President, Shionogi Healthcare Co., Ltd.
Corporate Strategy Division		
Senior Executive Officer, Senior Vice President, Corporate Strategy Division	Kohji Hanasaki	Senior Executive Officer, Vice President, Finance & Accounting Department
Vice President, Finance & Accounting Department	Kenji Matsuo	Senior Director, Global Innovation Office
Vice President, Corporate Communications Department, and Secretary Office	Yoshimasa Kyokawa	Associate Director, Corporate Communications Department
Senior Director, Product Management Office	Yousuke Miharū	Director, Corporate Planning Department
Senior Director, Supply Chain Management Strategy Office	Koji Ishii	Associate Director, EHS Office
Back office		
Vice President, Intellectual Property Department	Yoshiyuki Takeuchi	Vice President, API R&D Center
Corporate Officer, Vice President, Government Affairs Department	Masaaki Takeyasu	Corporate Officer, Senior Vice President, Global Business Division
Vice President, Corporate Social Responsibility Department	Hiroki Takagi	Vice President, Corporate Communications Department, and Secretary Office

Senior Director, EHS Office, Corporate Social Responsibility Department	Mikio Kabaki	Senior Director, EHS Office, Human Resources & Administration Department
Senior Director, Office for Children's Bright Future, Corporate Social Responsibility Department	Aki Ikebata	Director, Business Development Department
Senior Director, Office for Stewardship to Proper Use of Medicine, Corporate Social Responsibility Department	Takeshi Ishimure	Director, Government Affairs Department
Global group company		
Senior Executive Officer, President & CEO, Shionogi Inc.	Takayuki Yoshioka	Senior Executive Officer, Senior Vice President, SCM Division
Japanese group companies		
President, Shionogi Techno Advance Research Co., Ltd.	Kouji Ohno	Vice President, Research Laboratory for Development
President, Shionogi Analysis Center Co., Ltd	Makoto Kobayashi	Vice President, Shionogi Analytical R&D Center
President, Shionogi Career Development Center Co., Ltd	Yoshitaka Yamaguchi	President, Shionogi Techno Advance Research Co., Ltd.
President, Shionogi Smile Heart Co., Ltd*	Katsuya Hayashi	Director, Shionogi Administration Service Co., Ltd

*Effective on April 2, 2018


Forward-Looking Statements

This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, unavailability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

For further information, contact:

Corporate Communications Department
Shionogi & Co., Ltd.

Telephone: +81-6-6209-7885 Fax: +81-6-6229-9596



: Reorganization or Establishment of Organization